Vaccine Financial News

Analysts at Jefferies upgraded London-listed shares of GSK (GSK) to Buy and downgraded AstraZeneca (NASDAQ:AZN) to Hold in a note covering European Pharmaceutical stocks on Wednesday. The GSK price target was lifted to 1,900p from 1,550p per share, while the AZN price target was cut to 11,000p from 12,500p.

India registered about 12 lakh new cancer cases and 9.3 lakh deaths in 2019, becoming the second highest contributor to the disease burden in Asia for that year, according to a new study published in The Lancet Regional Health Southeast Asia journal. Researchers found that India, along with China and Japan, were the three leading countries in Asia in terms of number of new cases and deaths, where they say cancer has become a more significant public health threat with 94 lakh new cases and 56 lakh deaths in 2019. Of these, while China contributed the most with 48 lakh new cases and 27 lakh deaths, Japan recorded about 9 lakh new cases and 4.4 lakh deaths, the international team of researchers including those from the National Institute of Technology Kurukshetra and All India Institute of Medical Sciences (AIIMS), Jodhpur and Bathinda, said. «We examined the temporal patterns of 29 cancers in 49 Asian countries between 1990 and 2019 using estimates from the Global Burden of Disease, Injuries and Risk Factors 2019 Study (GBD 2019),» they wrote in their study. They found that in Asia, the leading cancer was that of tracheal, bronchus, and lung (TBL), resulting in an estimated 13 lakh cases and 12 lakh deaths. It was also found to be most frequent in men and third most frequent in women. Specifically among women, cervical cancer is ranked second or among top-5 cancers in several Asian countries.

The Great Escape, which tells the story of how human life improved over the past 250 years, particularly in terms of longevity and material living standards. But the past decadeHI has been unkind to my overwhelmingly positive account. My observation that “life is better now than at any time in history" may have been true in 2013, but it probably is not today, even for the typical person.

NEW DELHI : India’s first indigenously developed vaccine for the prevention of cervical cancer has the same efficacy as those procured from other countries, according to a recent study published in the medical journal Lancet. Serum Institute of India developed the vaccine, called Cervavac, to be administered to youngsters between ages 9 and 26. The vaccine, rolled out earlier this year, is available in private hospitals, where the cost has been set at ₹1,400-1,600.

India had recorded 865 new days on May 19. The number of daily cases had dropped to double-digits till December 5, but cases have again gone up after emergence of a new variant and cold weather conditions.

By Nidal al-Mughrabi and Arafat Barbakh

The Indian SARS-CoV-2 Consortium on Genomics (Insacog), the network of laboratories set up to monitor genomic variations of the coronavirus in India, held a meeting on Friday to review the situation amid a spike in Covid-19 cases and decided to hold another meeting next week to understand the proportion of JN.1 and other sub-variants. «JN.1 is gradually spreading out, but the good news is that there is no increase in hospitalisation yet,» said an Insacog member who attended the meeting. JN.1, a subvariant of Omicron with mild symptoms and few hospitalisations so far, has spread more in Gujarat, Goa and Maharashtra, the person said.

ALSO READ: Cancer and cardiovascular diseases top global claims frequency; respiratory disease ranks third: Report “I’d offered Sharmila ji the part played by Shabana ji, she was my first choice. But because of health reasons at that time, she couldn’t say yes.

Covid-19 to remain in home isolation for a period of seven days. Additionally, all symptomatic primary contacts of these individuals will also be tested. This decision was taken by a cabinet sub-committee on Covid-19, chaired by health minister Dinesh Gundu Rao, during their meeting at Vidhana Soudha on Tuesday.

media reports. Currently, the state has 34 cases of JN.1 variant. While speaking to news agency ANI, Karnataka Health Minister Dinesh Gundu Rao has that the government is well prepared and nothing is "alarming." "430 cases are active out of which 400 are in home isolation and the remaining are in hospital.

Karnataka government plans to procure 30,000 precautionary doses of Covid 19 vaccine for senior citizens and immunocompromised people in light of the rise in cases across the state, the newly created cabinet sub-committee announced on Tuesday. Karnataka will also have a daily testing target of 5000, making it the second highest testing state after Kerala, the committee added. While there are no restrictions on New Year celebrations and gatherings, there is a general advisory to wear masks at crowded places and observe Covid appropriate behaviour.

WHO said Tuesday the world needs to properly prepare for future pandemics after finally ending three years of Covid «crisis, pain and loss,» In his end-of-year message, World Health Organization director-general Tedros Adhanom Ghebreyesus said 2023 had marked a turning point in fighting major health challenges but had also brought «immense and avoidable suffering.»

«This is a milder version of Covid-19. Right now, we are not seeing any hospitalisation or severity of the disease, so would want to wait and watch and not do any procurement right away,» said a senior executive at a leading private hospital.

COVID-19 cases while the active caseload jumped to 4,054, according to Union Health Ministry data. The total fatalities were recorded at 5,33,334 (5.33 lakh) with one new death reported from Kerala in the previous 24 hours, the data updated at 8 am showed.

active cases rose to 3,742, according to the latest government data. A new strain "JN.1", classified as a "variant of interest" by the World Health Organization (WHO) last week, has been detected in India.

respiratory diseases, including due to COVID-19 and its new sub-variant JN.1, and influenza. The WHO also urged people to take protective measures. «The COVID-19 virus continues to evolve, change, and circulate in all countries globally.

Amit Shah on Sunday heaped praise on Prime Minister Narendra Modi's 'Atmanirbhar Bharat' campaign, saying it was singularly instrumental in lifting 60 crore people out of poverty. Waxing eloquent on the Centre's flagship campaign, which is aimed at taking the country towards self-reliance, Shah said the focus of the initiative is to make trade, industry and businesses and the 140 crore people of India 'Atmanirbhar'. "PM Modi has outlined his vision of an 'Atmanirbhar Bharat'. It is a visionary idea and campaign.

ANI, “It is more transmissible, it is spreading more rapidly, and it is gradually becoming a dominant variant. It is causing more infections but the data also suggests that it is not causing severe infections or hospitalisations.

Covid news LIVE: Amid a surge in COVID-19 cases in India and the detection of a subvariant JN.1, India SARS-CoV-2 Genomics Consortium (INSACOG) chief Dr NK Arora said that no additional dose of vaccine is needed against the subvariant at present.“Every week you hear something new coming up in different parts and then it spreads all over India. We have identified a large number of subvariants, over 400 subvariants, or mutations of this virus, and fortunately, none of these Omicron variants have really been associated with more severe disease or hospitalisation," Dr NK Arora told ANI.The total number of active cases of Covid-19 in the country was recorded at 3,420.The World Health Organization (WHO) has recently designated JN.1 as a variant of interest, differentiating it from its parent lineage BA.2.86.

advised to take precautions; otherwise, there is no need for any additional doses," NK Arora said while speaking with news agency ANI. The INSACOG chief asserted that they have identified over 400 subvariants of the Omicron variant of COVID-19, but none of the sub-variants is associated with more severe disease. "Every week you hear something new coming up in different parts and then it spreads all over India.

Covid case tally stood at 4.50 crore (4,50,07,964). The death toll was recorded at 5,33,332 with four new deaths -- two from Kerala, one each in Rajasthan and Karnataka -- reported in 24 hours, the data updated at 8 am stated. The number of people recuperated from the disease has increased to 4,44,71,212, and the national recovery rate stands at 98.81 percent, the health ministry said.